SCHEMBL19792933

SCHEMBL19792933

CC(C)C[C@H](NC(=O)OC(C)(C)C)C(=O)NS(=O)(=O)c1cccc2cc(C(=O)NC(C)(C)CC(C)(C)C)ncc12

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.39
AAK1 Q2M2I8 1/20 0.38
USP30 Q70CQ3 1/20 0.37
REN P00797 2/20 0.36
MAP1LC3B Q9GZQ8 1/20 0.36
MAP1LC3A Q9H492 1/20 0.36
BCL2 P10415 6/20 0.36
CTSS P25774 2/20 0.36
CTSK P43235 2/20 0.36
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
MCL1 Q07820 1/20 0.35
PTPRB P23467 1/20 0.35
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18019208 0.91 HDAC4 (0.37) BCL2CTSSCTSKCTSLMCL1
SCHEMBL17977183 0.90 USP30 (0.41) USP30
SCHEMBL19801191 0.79 P4HTM (0.37) EGFRMAPTNPSR1
SCHEMBL19792931 0.79 MMP1 (0.43) EGFRAAK1USP30RENMAP1LC3B
SCHEMBL18019199 0.78 CTSS (0.49) AAK1USP30RENMAP1LC3BMAP1LC3A
SCHEMBL18019211 0.78 AAK1 (0.37) EGFRAAK1USP30RENMAP1LC3B
SCHEMBL19792929 0.75 ADAM17 (0.49) AAK1BCL2CTSSCTSKCTSL
SCHEMBL17977191 0.74 POLB (0.41) EGFRMAPTMAPK1NPSR1
SCHEMBL18019164 0.72 PTGS2 (0.44) AAK1USP30RENMAP1LC3BMAP1LC3A
SCHEMBL19792924 0.71 CTSS (0.48) AAK1RENBCL2CTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180022696-A1 NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS THE LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) 2018-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180022696-A1 NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS AARS1, GARS1, ASNS EGFR 2744/4885AAK1 2180/4885USP30 1322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.